16.3 Epidemiology of Hypertension, Diabetes & Cancer in India
Key Takeaways
- Non-communicable diseases (NCDs) account for over 65% of total mortality in India, driven by the epidemiological transition and shared modifiable behavioral and metabolic risk factors.
- The 'Rule of Halves' in hypertension epidemiology underscores that ~50% of hypertensives are diagnosed, ~50% of diagnosed receive treatment, and ~50% of treated achieve target blood pressure control.
- India Hypertension Control Initiative (IHCI) enforces standardized drug protocols (Amlodipine step-up), uninterrupted drug supply, and patient tracking to achieve high population-level BP control.
- Diabetes screening under the National Programme for Prevention and Control of NCDs (NP-NCD) target all adults aged ≥30 years using the Community Risk Assessment Checklist (CBAC score ≥4) and capillary blood glucose testing.
- Visual Inspection with Acetic Acid (VIA) is the frontline population-based screening modality for cervical cancer in primary healthcare settings across India for women aged 30-65 years.
Epidemiology of Hypertension, Diabetes & Cancer in India
India is experiencing a rapid epidemiological transition. Non-communicable diseases (NCDs)—predominantly cardiovascular diseases, diabetes mellitus, cancers, and chronic respiratory diseases—now account for over 65% of all deaths in India. For the UPSC Combined Medical Services (CMS) exam, mastery of NCD epidemiological metrics, national screening protocols, and public health control initiatives is vital.
1. The Epidemiological Transition & Shared Risk Factors
- Epidemiological Transition: Shift in disease burden from communicable, maternal, and nutritional conditions to chronic non-communicable diseases.
- Shared Modifiable Behavioral Risk Factors: Tobacco use (smoked and smokeless), harmful alcohol consumption, unhealthy diet (high sodium >5 g/day, high trans-fats, low fruit/vegetable intake <400 g/day), and physical inactivity (<150 minutes of moderate-intensity aerobic exercise per week).
- Shared Metabolic Risk Factors: Overweight/obesity (BMI ≥23 kg/m² for South Asians), elevated blood pressure, hyperglycemia, and hyperlipidemia.
- Global & National Targets: WHO 25×25 Target (25% relative reduction in premature NCD mortality by 2025/2030) and the National NCD Monitoring Framework (10 targets and 21 indicators).
2. Hypertension Epidemiology & The IHCI Framework
Disease Burden & The "Rule of Halves"
- Prevalence in India: Affects approximately 28–30% of Indian adults (NFHS-5 data).
- The Rule of Halves in Hypertension:
- Only half of all individuals with hypertension are aware of their status (diagnosed).
- Only half of those diagnosed receive medical treatment.
- Only half of those treated achieve target blood pressure control (BP <140/90 mmHg).
- Net Result: Only ~12.5% of all hypertensive individuals in an unmanaged population have controlled blood pressure.
Diagnostic Classifications (JNC-8 / ACC-AHA / ICMR Guidelines)
- Normal Blood Pressure: Systolic <120 mmHg AND Diastolic <80 mmHg.
- Elevated / Pre-hypertension: Systolic 120–129 mmHg AND Diastolic <80 mmHg.
- Stage 1 Hypertension: Systolic 130–139 mmHg OR Diastolic 80–89 mmHg (ACC/AHA) / 140–159 / 90–99 mmHg (JNC-8/ICMR).
- Stage 2 Hypertension: Systolic ≥140 mmHg OR Diastolic ≥90 mmHg (ACC/AHA) / ≥160 / ≥100 mmHg (JNC-8/ICMR).
India Hypertension Control Initiative (IHCI)
Launched to accelerate blood pressure control nationwide, IHCI relies on 5 Core Pillars:
- Standardized Drug-Treatment Protocol: Simple step-up protocol using long-acting, once-daily antihypertensives.
- Step 1: Initiate Amlodipine 5 mg once daily.
- Step 2: Increase to Amlodipine 10 mg once daily if BP remains uncontrolled after 30 days.
- Step 3: Add Telmisartan 40 mg once daily.
- Step 4: Increase to Telmisartan 80 mg once daily.
- Step 5: Add Chlorthalidone 12.5 mg or Hydrochlorothiazide 12.5 mg once daily.
- Uninterrupted Drug Supply: Procurement of 3 primary protocol drugs at primary health centre level.
- Team-Based Care: Task-sharing among Medical Officers, Staff Nurses, ANMs, and ASHAs.
- Patient-Centered Services: 30-day drug refill policy and decentralization to Ayushman Arogya Mandirs (HWC).
- Digital Information System: Patient tracking via simple digital registers / IHCI mobile application.
3. Diabetes Mellitus Epidemiology & Population Control
Disease Burden in India (ICMR-INDIAB Study)
- India is frequently termed the "Diabetes Capital of the World," with over 101 million adults living with diabetes and 136 million adults with prediabetes.
- Urban prevalence (~16–20%) remains higher than rural (~8–10%), but rural prevalence is rapidly increasing.
Diagnostic Thresholds (ICMR / WHO Guidelines)
| Category | Fasting Plasma Glucose (FPG) | 2-Hour 75g Oral Glucose Tolerance Test (OGTT) | HbA1c Level |
|---|---|---|---|
| Normal | < 100 mg/dL (5.6 mmol/L) | < 140 mg/dL (7.8 mmol/L) | < 5.7% |
| Prediabetes (IFG / IGT) | 100–125 mg/dL (Impaired Fasting Glucose) | 140–199 mg/dL (Impaired Glucose Tolerance) | 5.7% – 6.4% |
| Diabetes Mellitus | ≥ 126 mg/dL (7.0 mmol/L) | ≥ 200 mg/dL (11.1 mmol/L) | ≥ 6.5% |
Random Blood Glucose: ≥200 mg/dL in the presence of classic hyperosmolar symptoms (polyuria, polydipsia, unexplained weight loss) is diagnostic of diabetes.
Population Screening under NP-NCD
- Target Group: All adults aged ≥30 years presenting to primary healthcare facilities or screened in the community.
- Tool: Community Based Risk Assessment Checklist (CBAC): Administered by ASHAs. Evaluates age, tobacco use, alcohol consumption, waist circumference, physical activity, and family history of NCDs. Individuals with a CBAC score ≥ 4 are prioritized for point-of-care Capillary Blood Glucose (CBG) testing using handheld glucometers.
4. Cancer Epidemiology & Screening Protocols under NP-NCD
Epidemiology of Cancers in India
- Males: Lip & Oral Cavity Cancer is the leading cancer site (due to widespread use of chewable smokeless tobacco products like gutka, khaini, and betel quid), followed by Lung, Stomach, and Esophagus cancers.
- Females: Breast Cancer is the most common cancer site and leading cause of cancer mortality (surpassing cervical cancer in urban and semi-urban India), followed by Cervical Cancer and Oral Cavity cancer.
NP-NCD Population-Based Cancer Screening (PBS) Guidelines
Under the National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD), population-based screening for 3 common cancers (Cervical, Breast, Oral) is conducted at Ayushman Arogya Mandirs (Health & Wellness Centres) for all individuals aged 30 to 65 years every 5 years:
| Cancer Type | Target Group | Frontline Screening Modality | Key Clinical Procedure & Positive Finding |
|---|---|---|---|
| Cervical Cancer | Women aged 30–65 years | Visual Inspection with Acetic Acid (VIA) every 5 years | Application of 3–5% freshly prepared dilute acetic acid to the cervix. Inspection after 1 minute: Appearance of an opaque, dense acetowhite lesion near the squamocolumnar junction indicates a POSITIVE test → Refer for Colposcopy / Cryotherapy. |
| Breast Cancer | Women aged 30–65 years | Clinical Breast Examination (CBE) every 5 years | Systematic inspection and palpation of breasts and axillary lymph nodes by trained female health workers (ANMs/Nurses/MOs). Positive finding: Palpable hard painless mass, skin dimpling, or nipple retraction → Refer for Mammography / Ultrasound / FNAC. |
| Oral Cancer | Men & Women aged ≥30 years | Oral Visual Examination (OVE) every 5 years | Systematic visual examination and bimanual palpation of the entire oral cavity under good light. Positive finding: Leukoplakia (white patch), Erythroplakia (red patch), or non-healing indurated ulcer >2 weeks → Refer for Biopsy. |
In hypertension epidemiology, which of the following statements correctly summarizes the 'Rule of Halves'?
Under the National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD), what is the recommended screening method and target interval for cervical cancer in primary health centers in India?
According to ICMR guidelines, which laboratory values define Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)?
Under the standardized IHCI treatment protocol, what is the initial first-line antihypertensive medication and starting dose recommended at the primary health care level?